[Clinical analysis on side effects of long-term oral administration of futraful to out-patients].
Ninety-six cases of cancer patients were treated with long-term oral administration of Futraful ranging more than one to five years. Group A consisted of 57 cases receiving the drug for 1-2 years and Group B of 39 cases receiving the drug for 3-5 years. In Group A abnormality of TTT was observed in 49% and also abnormality of LHD in 32% of the patients, abnormalities of hemoglobin, leucocyte count, lymphocyte per cent, GOT, GPT, ALP, Bilirubin and ZST were respectively reported in 10-20%. On the other hand, in Group B abnormalities of TTT (64%), hemoglobin (26%), LDH (21%) were observed as well as abnormalities 10-20% of leucocyte count, lymphocyte, GOT, and ALP in each approximately 10-20% of the patients. But all of the disorders were not severe and clinically not serious. These results suggested and safety of long-term oral administration of Futraful to out-patients.
D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D010045:Outpatients; D012709:Serum Albumin / Q000032:analysis; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*
D001798:Blood Proteins; D012709:Serum Albumin; D005641:Tegafur; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005472:Fluorouracil